{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T03:59:33Z","timestamp":1772164773458,"version":"3.50.1"},"reference-count":51,"publisher":"American Association for Cancer Research (AACR)","issue":"6","license":[{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015338","name":"HHS | NIH | NCI | Cancer Moonshot","doi-asserted-by":"publisher","award":["U54 CA224083"],"award-info":[{"award-number":["U54 CA224083"]}],"id":[{"id":"10.13039\/100015338","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015338","name":"HHS | NIH | NCI | Cancer Moonshot","doi-asserted-by":"publisher","award":["3U54CA224083-03S2A"],"award-info":[{"award-number":["3U54CA224083-03S2A"]}],"id":[{"id":"10.13039\/100015338","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031022","name":"HHS | NIH | NCI | Center for Cancer Research","doi-asserted-by":"publisher","award":["P30CA091842"],"award-info":[{"award-number":["P30CA091842"]}],"id":[{"id":"10.13039\/100031022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008382","name":"Stichting A Sister's Hope","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100008382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>The PI3K pathway regulates essential cellular functions and promotes chemotherapy resistance. Activation of PI3K pathway signaling is commonly observed in triple-negative breast cancer (TNBC). However previous studies that combined PI3K pathway inhibitors with taxane regimens have yielded inconsistent results. We therefore set out to examine whether the combination of copanlisib, a clinical grade pan-PI3K inhibitor, and eribulin, an antimitotic chemotherapy approved for taxane-resistant metastatic breast cancer, improves the antitumor effect in TNBC. A panel of eight TNBC patient-derived xenograft (PDX) models was tested for tumor growth response to copanlisib and eribulin, alone or in combination. Treatment-induced signaling changes were examined by reverse phase protein array, immunohistochemistry (IHC) and 18F-fluorodeoxyglucose PET (18F-FDG PET). Compared with each drug alone, the combination of eribulin and copanlisib led to enhanced tumor growth inhibition, which was observed in both eribulin-sensitive and -resistant TNBC PDX models, regardless of PI3K pathway alterations or PTEN status. Copanlisib reduced PI3K signaling and enhanced eribulin-induced mitotic arrest. The combination enhanced induction of apoptosis compared with each drug alone. Interestingly, eribulin upregulated PI3K pathway signaling in PDX tumors, as demonstrated by increased tracer uptake by 18F-FDG PET scan and AKT phosphorylation by IHC. These changes were inhibited by the addition of copanlisib. These data support further clinical development for the combination of copanlisib and eribulin and led to a phase I\/II trial of copanlisib and eribulin in patients with metastatic TNBC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>In this research, we demonstrated that the pan-PI3K inhibitor copanlisib enhanced the cytotoxicity of eribulin in a panel of TNBC PDX models. The improved tumor growth inhibition was irrespective of PI3K pathway alteration and was corroborated by the enhanced mitotic arrest and apoptotic induction observed in PDX tumors after combination therapy compared with each drug alone. These data provide the preclinical rationale for the clinical testing in TNBC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-24-0047","type":"journal-article","created":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T08:59:59Z","timestamp":1715158799000},"page":"1430-1440","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models"],"prefix":"10.1158","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6904-3351","authenticated-orcid":true,"given":"Zhanfang","family":"Guo","sequence":"first","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2759-3072","authenticated-orcid":true,"given":"Jingqin","family":"Luo","sequence":"additional","affiliation":[{"name":"2Division of Public Health Science, Siteman Cancer Center Biostatistics Core, Washington University School of Medicine, St. Louis, Missouri."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0365-8954","authenticated-orcid":true,"given":"R. Jay","family":"Mashl","sequence":"additional","affiliation":[{"name":"3Department of Medicine, McDonnell Genome Institute, Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7521-8157","authenticated-orcid":true,"given":"Jeremy","family":"Hoog","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8006-1032","authenticated-orcid":true,"given":"Piyush","family":"Maiti","sequence":"additional","affiliation":[{"name":"4Mallinckrodt Institute of Radiology, St. Louis, Missouri."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3249-4906","authenticated-orcid":true,"given":"Nikki","family":"Fettig","sequence":"additional","affiliation":[{"name":"4Mallinckrodt Institute of Radiology, St. Louis, Missouri."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7141-8354","authenticated-orcid":true,"given":"Sherri R.","family":"Davies","sequence":"additional","affiliation":[{"name":"5Department of Surgery, Washington University School of Medicine, St. Louis, Missouri."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8569-7131","authenticated-orcid":true,"given":"Rebecca","family":"Aft","sequence":"additional","affiliation":[{"name":"5Department of Surgery, Washington University School of Medicine, St. Louis, Missouri."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8024-2736","authenticated-orcid":true,"given":"Jason M.","family":"Held","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6964-9612","authenticated-orcid":true,"given":"Ramaswamy","family":"Govindan","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1517-2975","authenticated-orcid":true,"given":"Li","family":"Ding","sequence":"additional","affiliation":[{"name":"3Department of Medicine, McDonnell Genome Institute, Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9508-7249","authenticated-orcid":true,"given":"Shunqiang","family":"Li","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3992-1793","authenticated-orcid":true,"given":"Cornelius","family":"von Morze","sequence":"additional","affiliation":[{"name":"4Mallinckrodt Institute of Radiology, St. Louis, Missouri."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7868-6231","authenticated-orcid":true,"given":"Gerburg M.","family":"Wulf","sequence":"additional","affiliation":[{"name":"6Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3204-457X","authenticated-orcid":true,"given":"Kooresh I.","family":"Shoghi","sequence":"additional","affiliation":[{"name":"4Mallinckrodt Institute of Radiology, St. Louis, Missouri."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8156-7492","authenticated-orcid":true,"given":"Cynthia X.","family":"Ma","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2024,6,5]]},"reference":[{"key":"2024060514012907000_bib1","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2664","article-title":"Targeting PI3K signalling in cancer: opportunities, challenges and limitations","volume":"9","author":"Engelman","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"2024060514012907000_bib2","doi-asserted-by":"crossref","first-page":"R101","DOI":"10.1186\/bcr2204","article-title":"Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells","volume":"10","author":"Marty","year":"2008","journal-title":"Breast Cancer Res"},{"key":"2024060514012907000_bib3","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/ijc.24831","article-title":"PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality","volume":"126","author":"L\u00f3pez-Knowles","year":"2010","journal-title":"Int J Cancer"},{"key":"2024060514012907000_bib4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Cancer Genome Atlas Network","year":"2012","journal-title":"Nature"},{"key":"2024060514012907000_bib5","doi-asserted-by":"crossref","first-page":"22231","DOI":"10.1073\/pnas.1015245107","article-title":"Inositol polyphosphate 4-phosphatase II regulates PI3K\/Akt signaling and is lost in human basal-like breast cancers","volume":"107","author":"Fedele","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024060514012907000_bib6","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1368-7646(02)00120-6","article-title":"Activation of the PI3K\/Akt pathway and chemotherapeutic resistance","volume":"5","author":"West","year":"2002","journal-title":"Drug Resist Updat"},{"key":"2024060514012907000_bib7","first-page":"1527","article-title":"Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor\/medulloblastoma models as single agent and in combination chemotherapy","volume":"61","author":"Geoerger","year":"2001","journal-title":"Cancer Res"},{"key":"2024060514012907000_bib8","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1182\/blood-2002-11-3429","article-title":"Survival of acute myeloid leukemia cells requires PI3 kinase activation","volume":"102","author":"Xu","year":"2003","journal-title":"Blood"},{"key":"2024060514012907000_bib9","first-page":"1982","article-title":"Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro","volume":"55","author":"Shi","year":"1995","journal-title":"Cancer Res"},{"key":"2024060514012907000_bib10","doi-asserted-by":"crossref","first-page":"e2020","DOI":"10.1038\/cddis.2015.363","article-title":"Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells","volume":"6","author":"Hu","year":"2015","journal-title":"Cell Death Dis"},{"key":"2024060514012907000_bib11","doi-asserted-by":"crossref","first-page":"16158","DOI":"10.1073\/pnas.0702596104","article-title":"Activation of the PTEN\/mTOR\/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance","volume":"104","author":"Zhou","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024060514012907000_bib12","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.ejca.2012.02.053","article-title":"Effects of the combination of RAD001 and docetaxel on breast cancer stem cells","volume":"48","author":"Zhang","year":"2012","journal-title":"Eur J Cancer"},{"key":"2024060514012907000_bib13","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1358\/dot.2010.46.9.1519020","article-title":"Eribulin mesilate, a halichondrin B analogue, in the treatment of breast cancer","volume":"46","author":"Mani","year":"2010","journal-title":"Drugs Today"},{"key":"2024060514012907000_bib14","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet"},{"key":"2024060514012907000_bib15","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10549-014-3144-y","article-title":"Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies","volume":"148","author":"Twelves","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"2024060514012907000_bib16","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1111\/cas.12488","article-title":"Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models","volume":"105","author":"Funahashi","year":"2014","journal-title":"Cancer Sci"},{"key":"2024060514012907000_bib17","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1038\/bjc.2014.80","article-title":"Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states","volume":"110","author":"Yoshida","year":"2014","journal-title":"Br J Cancer"},{"key":"2024060514012907000_bib18","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.18632\/oncotarget.26960","article-title":"PI3K inhibition enhances the anti-tumor effect of eribulin in triple negative breast cancer","volume":"10","author":"Rajput","year":"2019","journal-title":"Oncotarget"},{"key":"2024060514012907000_bib19","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1158\/1535-7163.MCT-12-0993-T","article-title":"BAY 80\u20136946 is a highly selective intravenous PI3K inhibitor with potent p110\u03b1 and p110\u03b4 activities in tumor cell lines and xenograft models","volume":"12","author":"Liu","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"2024060514012907000_bib20","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/annonc\/mdw282","article-title":"First-in-human phase I study of copanlisib (BAY 80\u20136946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas","volume":"27","author":"Patnaik","year":"2016","journal-title":"Ann Oncol"},{"key":"2024060514012907000_bib21","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.celrep.2013.08.022","article-title":"Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts","volume":"4","author":"Li","year":"2013","journal-title":"Cell Rep"},{"key":"2024060514012907000_bib22","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1158\/1535-7163.MCT-13-0159","article-title":"Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models","volume":"12","author":"Xu","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"2024060514012907000_bib23","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1158\/0008-5472.CAN-17-1990","article-title":"Mass spectrometry-based proteomics reveals potential roles of NEK9 and MAP2K4 in resistance to PI3K inhibition in triple-negative breast cancers","volume":"78","author":"Mundt","year":"2018","journal-title":"Cancer Res"},{"key":"2024060514012907000_bib24","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/biostatistics\/kxj037","article-title":"Adjusting batch effects in microarray expression data using empirical Bayes methods","volume":"8","author":"Johnson","year":"2007","journal-title":"Biostatistics"},{"key":"2024060514012907000_bib25","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1200\/JCO.2010.31.6950","article-title":"Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype\u2013ACOSOG Z1031","volume":"29","author":"Ellis","year":"2011","journal-title":"J Clin Oncol"},{"key":"2024060514012907000_bib26","doi-asserted-by":"crossref","first-page":"e0157368","DOI":"10.1371\/journal.pone.0157368","article-title":"Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection","volume":"11","author":"Lehmann","year":"2016","journal-title":"PLoS One"},{"key":"2024060514012907000_bib27","doi-asserted-by":"crossref","first-page":"147","DOI":"10.4137\/CIN.S9983","article-title":"TNBCtype: a subtyping tool for triple-negative breast cancer","volume":"11","author":"Chen","year":"2012","journal-title":"Cancer Inform"},{"key":"2024060514012907000_bib28","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J Clin Invest"},{"key":"2024060514012907000_bib29","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/nature08989","article-title":"Genome remodelling in a basal-like breast cancer metastasis and xenograft","volume":"464","author":"Ding","year":"2010","journal-title":"Nature"},{"key":"2024060514012907000_bib30","doi-asserted-by":"crossref","first-page":"14864","DOI":"10.1038\/ncomms14864","article-title":"Proteogenomic integration reveals therapeutic targets in breast cancer xenografts","volume":"8","author":"Huang","year":"2017","journal-title":"Nat Commun"},{"key":"2024060514012907000_bib31","doi-asserted-by":"crossref","first-page":"5086","DOI":"10.1038\/s41467-021-25177-3","article-title":"Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment","volume":"12","author":"Sun","year":"2021","journal-title":"Nat Commun"},{"key":"2024060514012907000_bib32","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"2024060514012907000_bib33","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/nm.3954","article-title":"High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response","volume":"21","author":"Gao","year":"2015","journal-title":"Nat Med"},{"key":"2024060514012907000_bib34","first-page":"1611","article-title":"Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions","volume":"32","author":"Towle","year":"2012","journal-title":"Anticancer Res"},{"key":"2024060514012907000_bib35","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.critrevonc.2011.03.002","article-title":"Eribulin \u2013 a review of preclinical and clinical studies","volume":"81","author":"Swami","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"2024060514012907000_bib36","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00280-017-3369-7","article-title":"Eribulin shows high concentration and long retention in xenograft tumor tissues","volume":"80","author":"Sugawara","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"2024060514012907000_bib37","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1158\/1078-0432.CCR-08-2429","article-title":"A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies","volume":"15","author":"Goel","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2024060514012907000_bib38","first-page":"009","article-title":"Identification of combinatorial drugs that synergistically kill both eribulin-sensitive and eribulin-insensitive tumor cells","volume":"1","author":"Rickles","year":"2015","journal-title":"Glob J Cancer Ther"},{"key":"2024060514012907000_bib39","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/S1470-2045(17)30450-3","article-title":"Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"18","author":"Kim","year":"2017","journal-title":"Lancet Oncol"},{"key":"2024060514012907000_bib40","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1200\/JCO.19.00368","article-title":"Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial","volume":"38","author":"Schmid","year":"2020","journal-title":"J Clin Oncol"},{"key":"2024060514012907000_bib41","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s10549-021-06450-x","article-title":"Ipatasertib plus paclitaxel for PIK3CA\/AKT1\/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial","volume":"191","author":"Turner","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"2024060514012907000_bib42","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1158\/1078-0432.CCR-20-4879","article-title":"Clinical and biomarker results from phase I\/II study of PI3K inhibitor alpelisib plus nab-paclitaxel in HER2-negative metastatic breast cancer","volume":"27","author":"Sharma","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2024060514012907000_bib43","first-page":"401","article-title":"Mesenchymal-epithelial transition and tumor vascular remodeling in eribulin chemotherapy for breast cancer","volume":"38","author":"Kashiwagi","year":"2018","journal-title":"Anticancer Res"},{"key":"2024060514012907000_bib44","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41416-019-0556-9","article-title":"Eribulin rapidly inhibits TGF-\u03b2-induced Snail expression and can induce Slug expression in a Smad4-dependent manner","volume":"121","author":"Kaul","year":"2019","journal-title":"Br J Cancer"},{"key":"2024060514012907000_bib45","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1158\/1078-0432.CCR-12-1558","article-title":"An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance","volume":"19","author":"Byers","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2024060514012907000_bib46","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1158\/1078-0432.CCR-15-2276","article-title":"Strategically timing inhibition of phosphatidylinositol 3-kinase to maximize therapeutic index in estrogen receptor alpha-positive, PIK3CA-mutant breast cancer","volume":"22","author":"Yang","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2024060514012907000_bib47","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1158\/1535-7163.MCT-15-0687","article-title":"Intermittent high-dose scheduling of AZD8835, a novel selective inhibitor of PI3K\u03b1 and PI3K\u03b4, demonstrates treatment strategies for PIK3CA-dependent breast cancers","volume":"15","author":"Hudson","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"2024060514012907000_bib48","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1038\/s41416-021-01293-1","article-title":"PI3K activation promotes resistance to eribulin in HER2-negative breast cancer","volume":"124","author":"Gris-Oliver","year":"2021","journal-title":"Br J Cancer"},{"key":"2024060514012907000_bib49","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1158\/1078-0432.CCR-21-2498","article-title":"Functional mapping of AKT signaling and biomarkers of response from the FAIRLANE trial of neoadjuvant ipatasertib plus paclitaxel for triple-negative breast cancer","volume":"28","author":"Shi","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2024060514012907000_bib50","doi-asserted-by":"crossref","first-page":"5594514","DOI":"10.1155\/2021\/5594514","article-title":"Early changes in [18F]FDG uptake as a readout for PI3K\/Akt\/mTOR targeted drugs in HER-2-positive cancer xenografts","volume":"2021","author":"Dockx","year":"2021","journal-title":"Mol Imaging"},{"key":"2024060514012907000_bib51","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2013.54.0518","article-title":"Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"32","author":"Mayer","year":"2014","journal-title":"J Clin Oncol"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-24-0047\/3451602\/crc-24-0047.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/6\/1430\/3459827\/crc-24-0047.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/6\/1430\/3459827\/crc-24-0047.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T10:02:48Z","timestamp":1717581768000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/4\/6\/1430\/745713\/Evaluation-of-Copanlisib-in-Combination-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,5]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6,5]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-24-0047","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.25976507","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25976513","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25976525","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25976501","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25976486","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25976531","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25976501.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25976498","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25976492","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25976528.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25976510.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25976486.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25976492.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25976519.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25976525.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25976489.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25976519","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25976516.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25976528","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25976522.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25976504","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25976516","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25976489","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25976522","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25976498.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25976534","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25976513.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25976495.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25976510","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25976507.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25976495","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25976531.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25976504.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25976534.v1","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7270694.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.7270694","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,5]]}}}